Answers are grounded in this paper and cite their sources.
Although MHC-homo-iPSCs are preferred to avoid immune rejection, MHC-mismatched iPSC-CMs can also induce comparable cardiac functional recovery at late follow-up, suggesting that MHC-mismatched iPSC-based cardiac regenerative therapy with immunosuppressants is a feasible option for treating heart failure in clinical settings.
No takes yet. Share an insight, caveat, or question.
Kashiyama et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: